Črna gora - hrvaščina - CInMED-Institut za ljekove i medicinska sredstva Crne Gore

druŠtvo za trgovinu na veliko farmaceutskim proizvodima "glosarij" d.o.o.-podgorica - lornoksikam - film tableta - 8mg

Črna gora - hrvaščina - CInMED-Institut za ljekove i medicinska sredstva Crne Gore

"evropa lek pharma" doo podgorica - acetilsalicilna kiselina - tableta - 500mg

Črna gora - hrvaščina - CInMED-Institut za ljekove i medicinska sredstva Crne Gore

druŠtvo sa ograniČenom odgovornoŠĆu "nobel" podgorica - meloksikam - tableta - 15mg

Črna gora - hrvaščina - CInMED-Institut za ljekove i medicinska sredstva Crne Gore

druŠtvo sa ograniČenom odgovornoŠĆu "nobel" podgorica - meloksikam - tableta - 15mg

Črna gora - hrvaščina - CInMED-Institut za ljekove i medicinska sredstva Crne Gore

druŠtvo sa ograniČenom odgovornoŠĆu "nobel" podgorica - deksketoprofen - film tableta - 25mg

Črna gora - hrvaščina - CInMED-Institut za ljekove i medicinska sredstva Crne Gore

"evropa lek pharma" doo podgorica - acetilsalicilna kiselina, askorbinska kiselina - Šumeća tableta - 400mg + 240mg

Evropska unija - hrvaščina - EMA (European Medicines Agency)

daiichi sankyo europe gmbh - trastuzumab deruxtecan - neoplazme dojki - antineoplastična sredstva - breast cancerher2-positive breast cancerenhertu as monotherapy is indicated for the treatment of adult patients with unresectable or metastatic her2-positive breast cancer who have received one or more prior anti-her2-based regimens. her2-low breast cancerenhertu as monotherapy is indicated for the treatment of adult patients with unresectable or metastatic her2-low breast cancer who have received prior chemotherapy in the metastatic setting or developed disease recurrence during or within 6 months of completing adjuvant chemotherapy (see section 4. non-small cell lung cancer (nsclc)enhertu as monotherapy is indicated for the treatment of adult patients with advanced nsclc whose tumours have an activating her2 (erbb2) mutation and who require systemic therapy following platinum-based chemotherapy with or without immunotherapy. gastric cancerenhertu as monotherapy is indicated for the treatment of adult patients with advanced her2-positive gastric or gastroesophageal junction (gej) adenocarcinoma who have received a prior trastuzumab-based regimen.

Evropska unija - hrvaščina - EMA (European Medicines Agency)

pfizer europe ma eeig - crizotinib - karcinom, ne-malih stanica pluća - antineoplastična sredstva - xalkori as monotherapy is indicated for:the first‑line treatment of adults with anaplastic lymphoma kinase (alk)‑positive advanced non‑small cell lung cancer (nsclc)the treatment of adults with previously treated anaplastic lymphoma kinase (alk)‑positive advanced non‑small cell lung cancer (nsclc)the treatment of adults with ros1‑positive advanced non‑small cell lung cancer (nsclc)the treatment of paediatric patients (age ≥6 to.

Evropska unija - hrvaščina - EMA (European Medicines Agency)

eli lilly nederland b.v. - necitumumab - karcinom, ne-malih stanica pluća - antineoplastična sredstva - portrazza u kombinaciji s gemcitabinom i cisplatinom kemoterapija je indicirana za liječenje odraslih bolesnika s lokalno uznapredovalim ili metastatskim epidermalnog čimbenika rasta receptora (egfr) izražava pločastih ne-malih stanica raka pluća ne primali kemoterapiju za ovo stanje.

Evropska unija - hrvaščina - EMA (European Medicines Agency)

novartis europharm limited  - pazopanib - karcinom, stanice bubrega - antineoplastična sredstva - Почечно srpastih stanica karcinom Вотриент (ОКВ)navodi u odraslih za prvu liniju liječenja održao почечно-stanica raka (pkr) i za pacijente koji su primili do цитокиновой terapija u kasnijim fazama bolesti. sarkom mekog tkiva (its)Вотриент indiciran za liječenje odraslih bolesnika s selektivna podtipovi modernih sarkom mekog tkiva (smt), koji je dobio ranije kemoterapije za метастатической bolesti ili koji su napredovali u roku od 12 mjeseci nakon (neo)adjuvantne terapije. učinkovitost i sigurnost je samo u nekim СЦ гистологических podtipova tumora.